drug
difamilast
Marketedupdated 3mo agoby Acrotech Biopharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying difamilast
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 1, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 31, 2036compositionUS 10588893
- Mar 1, 2028compositionUS RE467921.5y
FDA exclusivities (1)
- Feb 12, 2031NCENew Chemical Entity (5y)4.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that